Arcturus Therapeutics Ltd.
http://arcturusrx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arcturus Therapeutics Ltd.
Coronavirus Notebook: EMA Publishes Veklury Clinical Data, Head Of UK Vaccines Taskforce Comes Under Fire
Transparency is the order of the day as Médecins Sans Frontières calls for more disclosure on vaccine deals signed by Sanofi/GSK and other companies.
Finance Watch: Biopharma Fundraising Impact Expected, But Not Apparent Yet
While COVID-19 shocked global financial markets and is expected to impact biopharma fundraising, investment in drug developers continues, including through two new venture capital funds totaling nearly $2bn. Also, Coherus issues debt to fund deals and MOMA launches with $86m in VC cash.
Finance Watch: Landos Raises $60m Series B Round Ahead Of Phase II Data In 2020
If Landos goes public late next year, its financing strategy will align with venture capital and IPO trends observed in a new Jefferies report. Also, D&D Pharmatech raises $137.1m in VC cash, Sonnet secures up to $100m and the CF Foundation commits up to $15m to Arcturus.
Deal Watch: Sanofi Further Opts Out Of CNS Tie-Up With Voyager
Sanofi returns two partnered assets to Voyager, further unraveling 2015 deal. Celgene drops Mereo cancer candidate ahead of merger with Bristol, while Ultragenyx and Arcturus expand their joint rare disease efforts.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
-
- Alcobra Ltd.
- Alcobra Pharma
- Arcturus Therapeutics, Inc.